What is the optimal (neo)adjuvant strategy of extremity high-risk soft tissue sarcomas (ESTS)?

Abstract

Currently, the standard treatment for extremity high-risk soft tissue sarcomas (ESTS) combines surgery and pre- or post-op radiation therapy (RT). In some selected cases, chemotherapy (CT) is incorporated into the therapeutic algorithm as a neoadjuvant approach to enable conservative management. Given the risk of local or metastatic relapse, this paper discusses the potential benefits of CT and RT in high-grade ESTs. The role of adjuvant chemotherapy in addition to neoadjuvant CT, the prognostic value of the pathological response to neoadjuvant treatment, and the role for an adjuvant "boost" following resection after pre-operative radiotherapy will be discussed.

• Authors: Saoussane Kharmoum, Jinane Kharmoum, Mariam Chraibi, Sylvie Bonvalot, Jean-Yves Blay, Mohammed Shimi
• Journal: Medical oncology (Northwood, London, England) (Med Oncol) Vol. 41 Issue 1 Pg. 16 (Dec 12 2023) ISSN: 1559-131X [Electronic] United States
• PMID: 38087013 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• Adjuvants, Immunologic

Topics

• Humans
• Expressed Sequence Tags
• Neoplasm Recurrence, Local (pathology)
• Extremities (pathology)
• Sarcoma (pathology)
• Soft Tissue Neoplasms (drug therapy)
• Neoadjuvant Therapy
• Chemotherapy, Adjuvant
• Adjuvants, Immunologic
• Radiotherapy, Adjuvant